Hepatitis C Caring Ambassadors Program Newsletter

June, 2005


In The News


Huge posters focus on hepatitis C



AVI BioPharma Submits IND for NEUGENE Antisense Drug Targeting Hepatitis C Virus



Canada Red Cross tries to put blood scandal to rest



Sexual transmission of HCV found in Swiss HIV-positive gay men



State cuts inmate hepatitis funds



Shorter Hepatitis C Treatment Works for Some



Nabi Biopharmaceuticals Gains Orphan Medicinal Product Designation For Civacir(TM) in Europe



Peregrine Pharmaceuticals Presents Data Supporting Broad Spectrum Anti-Viral Potential of  Tarvacin(TM) at BIO 2005



Aethlon Medical To Initiate Hepatitis-C Studies



Hepatitis C protease inhibitor, VX-950, reduces viral levels



Human Genome Sciences Initiates Phase 2b Clinical Trial of Albuferon(TM) in Combination With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C



Hepatitis C: hope on the distant horizon



Innogenetics sees three-year delay in hepatitis C vaccine launch - press report http://www.forbes.com/markets/feeds/afx/2005/06/15/afx2093249.html

How hepatitis-C virus evades immune system in acute and chronic infections


Researchers Create Infectious Hepatitis C Virus in a Test Tube



New Approach To Hepatitis C



Clinical Trials, Cohort Studies, Pilot Studies


Natural history of major complications in hepatitis C virus-related cirrhosis evaluated by per-rectal portal scintigraphy. Kawamura E, et al. World J Gastroenterol. 2005 Jul 7;11(25):3882-6.



Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy. El-Zayadi AR, et al. Liver Int. 2005 Aug;25(4):746-51.



Effect of interferon on incidence of hepatocellular carcinoma in patients with chronic hepatitis C.  Soga K, Shibasaki K, Aoyagi Y. Hepatogastroenterology. 2005 Jul-Aug;52(64):1154-8.



Effect of interferon, ribavirin and ursodeoxycholic acid in patients with hepatitis C infection. Ljubuncic P, et al. Hepatogastroenterology. 2005 Jul-Aug;52(64):1191-6.



Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin. Ferenci P, et al. J Hepatol. 2005 Jun 27; [Epub ahead of print]

Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Cox AL, et al. Hepatology. 2005 Jun 16;42(1):104-112 [Epub ahead of print] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15962289&query_hl=12 

Optimal dosing frequency of pegylated interferon alfa-2b monotherapy for chronic hepatitis C virus infection. Lurie Y, et al. Clin Gastroenterol Hepatol. 2005 Jun;3(6):610-5. 

Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Harrison SA, et al.  Clin Gastroenterol Hepatol. 2005 Jun;3(6):604-9. 

Gender and liver fibrosis in chronic hepatitis: the role of iron status.  Rigamonti C, et al. Aliment Pharmacol Ther. 2005 Jun;21(12):1445-1451. 

Comprehensive clinical assessment improves the accuracy of predicting cirrhosis in chronic hepatitis C. Gordon A, Bailey MJ, et al. J Gastroenterol Hepatol. 2005 Jun;20(6):825-32. 

Risk factors for hepatitis C virus infection in patients on long-term hemodialysis. Khokhar N, Alam AY, Naz F, Mahmud SN. J Coll Physicians Surg Pak. 2005 Jun;15(6):326-8. 

Pilot study of interferon gamma for chronic hepatitis C.  Rushbrook SM, et al. J Hepatol. 2005 Jul;43(1):67-71. Epub 2005 Apr 26. 

Systemic autoimmune diseases co-existing with chronic hepatitis C virus infection (the HISPAMEC Registry): patterns of clinical and immunological expression in 180 cases. Ramos-Casals M, et al. J Intern Med. 2005 Jun;257(6):549-57. 

Antioxidant levels in peripheral blood, disease activity and fibrotic stage in chronic hepatitis C. Bandara P, George J, McCaughan G, et al. Liver Int. 2005 Jun;25(3):518-26. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=pubmed  


Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.  Mangia A, et al. N Engl J Med. 2005 Jun 23;352(25):2609-17. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15972867&query_hl=13

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin.  Ferenci P, et al. J Hepatol. 2005 Jun 27; [Epub ahead of print]

Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C.  Liu CJ, et al. Antivir Ther. 2005;10(3):405-15. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15918331&query_hl=12 

Serum copper and zinc concentrations in patients with chronic hepatitis C. Cesur S, et al. J Infect. 2005 Jul;51(1):35-37. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15979488&query_hl=1 
Basic and Applied Science, Pre-Clinical Studies

Hepatitis C virus-core and non structural proteins lead to different effects on cellular antioxidant defenses.    Abdalla MY, et al. J Med Virol. 2005 Aug;76(4):489-97.       



A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepatitis C. Richardson MM, et al. J Med Genet. 2005 Jul;42(7):e45.



T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C.  Kaplan DE, et al.  Hepatology. 2005 Jun;41(6):1365-75. PMID: 15915458 [PubMed - in process]

Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection.  Rushbrook SM, et al. J Virol. 2005 Jun;79(12):7852-9. 
T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection.  Boettler T, et al. J Virol. 2005 Jun;79(12):7860-7. 

Serum adiponectin correlates with viral characteristics but not histologic features in patients with chronic hepatitis C. Liu CJ, et al. J Hepatol. 2005 Jun 16; [Epub ahead of print] http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15964656&query_hl=8

Inhibition of hepatitis C virus translation and subgenomic replication by siRNAs directed against highly conserved HCV sequence and cellular HCV cofactors.  Korf M, et al. J Hepatol. 2005 Jun 16; [Epub ahead of print]

Small Hairpin RNAs Efficiently Inhibit Hepatitis C IRES-Mediated Gene Expression in Human Tissue Culture Cells and a Mouse Model. Wang Q, et al.  Mol Ther. 2005 Jun 10; [Epub ahead of print]

Prediction of viremia for cases of hepatitis C virus (HCV) infection using a third-generation anti-HCV enzyme immunoassay test. Huang WS, et al. Hepatogastroenterology.2005 May-Jun;52(63):893-6.

Stable human lymphoblastoid cell lines constitutively expressing hepatitis C virus proteins.  Wolk B, et al.
J Gen Virol. 2005 Jun;86(Pt 6):1737-46. PMID: 15914852 [PubMed - in process]


HIV/HCV Coinfection

Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. Mocroft A, et al. AIDS Res Hum Retroviruses. 2005 Jun;21(6):527-36.



Epidemiology of chronic hepatitis C virus in patients infected by human immunodeficiency virus. Study of 767 patients. Rubio Caballero M, et al., Med Clin (Barc). 2005 Jun 11;125(2):56-8. Spanish.


Detection of Hepatitis C Virus (HCV) in Serum and Peripheral-Blood Mononuclear Cells from HCV-Monoinfected and HIV/HCV-Coinfected Persons. Blackard JT, et al. J Infect Dis. 2005 Jul 15;192(2):258-65. Epub 2005 Jun 7.

Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. Salmon-Ceron D, et al.  J Hepatol. 2005 Jun;42(6):799-805.

Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients.  Laguno M, et al. Antivir Ther. 2005;10(3):423-9. PMID: 15918333 [PubMed - indexed for MEDLINE]

Continuous release of hepatitis C virus (HCV) by peripheral blood mononuclear cells and B-lymphoblastoid cell-line cultures derived from HCV-infected patients.  Bare P, et al.  J Gen Virol. 2005 Jun;86(Pt 6):1717-27. PMID: 15914850 [PubMed - in process]
Complementary and Alternative Therapies

Effects of a new pharmacological complex (sylibin+vitamin E+phospholipids) on some markers of metabolic syndrome and of a liver fibrosis in patients with non-alcoholic fatty liver disease: a preliminary open pilot study. Trappoliere M, et al. Gastroenterol Dietol. 2005 Jun;51(2):193-9.

Inhibition effect of Chinese herbal medicine on transcription of hepatitis C virus structural gene in vitro. Dou J, Chen Q, Wang J.  World J Gastroenterol. 2005 Jun 21;11(23):3619-22. 

Herbal medicine Ninjinyoeito ameliorates ribavirin-induced anemia in chronic hepatitis C: A randomized controlled trial. Motoo Y, et al. World J Gastroenterol. 2005 Jul 14;11(26):4013-7.
Miscellaneous Works
Evolution over a 10 year period of the epidemiological profile of 1,726 newly diagnosed HCV patients in Belgium. Gerard C, et al. J Med Virol. 2005 Aug;76(4):503-10.        
Knowledge of hepatitis among active drug injectors at a syringe exchange program. Carey J, et al. J Subst Abuse Treat. 2005 Jul;29(1):47-53.
Hepatitis C virus infection among prisoners in the California state correctional system. Fox RK, et al. Clin Infect Dis. 2005 Jul 15;41(2):177-86.
Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. Payan C, et al. J Viral Hepat. 2005 Jul;12(4):405-13.
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: Results of the HALT-C cohort. Lok AS, et al. Hepatology. 2005 Jun 28; [Epub ahead of print]
Cost-effectiveness of interferon {alpha} or peginterferon {alpha} with ribavirin for histologically mild chronic hepatitis C. Grieve R, et al. Gut. 2005 Jun 30; [Epub ahead of print]
Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C.  Lackner C, et al.  Hepatology. 2005 Jun;41(6):1376-82.PMID: 15915455 [PubMed - in process]

Comparison of Qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and Quantitative (COBAS AMPLICOR HCV Monitor 2.0 versus VERSANT HCV RNA 3.0) Assays for Hepatitis C Virus (HCV) RNA Detection and Quantification: Impact on Diagnosis and Treatment of HCV Infections. Desombere I, et al. J Clin Microbiol. 2005 Jun;43(6):2590-7. 

Prediction of viremia for cases of hepatitis C virus (HCV) infection using a third-generation anti-HCV enzyme immunoassay test. Huang WS, et al. Hepatogastroenterology. 2005 May-Jun;52(63):893-6.

Cancer history and other personal factors affect quality of life in patients with Hepatitis C.
Olson SH, et al. Qual Life Outcomes. 2005 Jun 16;3(1):39 [Epub ahead of print]

Hepatitis C and health-related quality of life among patients with hemophilia.  Posthouwer D, et al. Haematologica. 2005 Jun;90(6):846-50.
Medical students' knowledge of sharps injuries. Elliott SK, Keeton A, Holt A., Clinical Microbiology, J Hosp Infect. 2005 Jun 1; [Epub ahead of print] 

Results of a hepatitis C general transfusion lookback program for patients who received blood products before July 1992. Williams JL, et al. Transfusion. 2005 Jun;45(6):1020-6.